Skip to content Skip to sidebar Skip to footer
0 items - $0.00 0

Surgical Treatment

HomeSurgical Treatment
Close

Surgical Treatment of Parkinson’s Disease

A comprehensive, evidence-based review of surgical interventions for Parkinson’s disease, with emphasis on deep brain stimulation — the most established surgical approach — and emerging neurosurgical technologies.

10.1 Deep Brain Stimulation (DBS)

Deep Brain Stimulation (DBS) is the gold standard surgical treatment for PD and the most effective intervention for refractory motor complications. DBS involves the chronic delivery of high-frequency electrical stimulation through permanently implanted electrodes in specific subcortical targets. A pulse generator (IPG), surgically implanted in the chest or abdomen, delivers continuous or programmed stimulation via leads tunneled subcutaneously to the electrodes.

Primary Targets

  • Subthalamic nucleus (STN): Most commonly targeted. STN-DBS reduces “off” time by ~60–70%, dyskinesias by ~60%, and allows 25–50% reduction in dopaminergic medication. The landmark EARLYSTIM trial demonstrated that STN-DBS was superior to best medical therapy in patients with early motor complications (4–5 years disease duration) on quality of life outcomes (Schuepbach et al., 2013, NEJM).
  • Globus pallidus internus (GPi): Alternative target; particularly effective for dyskinesias without reducing medication; may be preferred in patients with cognitive concerns, depression, or gait impairment as primary symptom. The VA/NIH COMPARE trial showed STN and GPi had equivalent overall outcomes at 2 years (Follett et al., 2010, NEJM).
  • Ventral intermediate nucleus of thalamus (Vim): Primarily targets tremor; effective for tremor-predominant PD but does not address bradykinesia or rigidity. Less commonly used for PD than STN or GPi.

Patient Selection Criteria

DBS is most appropriate for patients who:

  • Have a confirmed PD diagnosis (DaTscan and good levodopa response)
  • Suffer from disabling motor fluctuations and/or dyskinesias despite optimized pharmacotherapy
  • Are otherwise medically fit for surgery
  • Have adequate cognitive function (significant dementia is a relative contraindication)
  • Have realistic expectations and strong social support

Risks and Limitations

  • Surgical risks: Intracranial hemorrhage (~1–2%), stroke, infection (~3–5%), hardware malfunction
  • Stimulation-related: Dysarthria, gait/balance worsening, depression, impulsivity, weight gain, eyelid opening apraxia
  • DBS does not halt neurodegeneration — motor symptoms continue to progress, and axial symptoms (gait, balance, speech) typically do not respond as well as appendicular symptoms
  • Non-motor symptoms (autonomic dysfunction, cognitive decline, depression) generally not improved by DBS

10.2 Focused Ultrasound (FUS)

Magnetic resonance-guided focused ultrasound (MRgFUS) uses convergent ultrasound beams to create a precise, targeted thermal lesion deep in the brain without cranial incision. FDA-approved for unilateral thalamotomy for essential tremor (2016) and PD tremor (2018), and bilateral pallidotomy for dyskinesia (2023).

Advantages over DBS: no implanted hardware, no surgical risk of hemorrhage or infection, outpatient procedure, immediate feedback. Limitations: unilateral only (bilateral thalamotomy has high rates of speech and balance complications), irreversible lesion, requires MRI access, limited to tremor (thalamotomy) or dyskinesias (pallidotomy), not effective for bradykinesia or motor fluctuations (Krishna et al., 2018, Annals of Neurology).

10.3 Adaptive DBS & Emerging Technologies

Next-generation DBS systems incorporate local field potential (LFP) sensing to continuously monitor beta-band oscillations (pathologically elevated in PD “off” state) and deliver stimulation only when needed — so-called “adaptive” or “closed-loop” DBS. Early studies demonstrate that adaptive DBS achieves equivalent or superior symptom control while reducing stimulation by ~40%, potentially extending battery life and reducing side effects (Little et al., 2016, Journal of Neurology, Neurosurgery & Psychiatry). The ADAPT-PD clinical trial is currently evaluating adaptive DBS in a larger cohort.

Other emerging surgical approaches include: transcranial focused ultrasound neuromodulation (non-ablative, reversible), cortical stimulation (motor cortex, addressing gait and axial symptoms), and optogenetic DBS (cell-type specific stimulation, currently preclinical). Neurosurgical robotics are improving the accuracy and safety of DBS electrode implantation.

References: Follett et al. (2010) NEJM; Krishna et al. (2018) Ann Neurol; Little et al. (2016) JNNP; Schuepbach et al. (2013) NEJM.

Navigation: ← Pharmacological Treatment | Rehabilitation →